C4X Discovery has signed a licensing agreement with Indivior to further develop and commercialize C4XD’s oral Orexin-1 receptor antagonist (“C4X3256”) for the treatment of addiction.    C4X3256 aims to treat addiction by targeting the “craving” process itself and, therefore, can be applied across a broad range of substance use disorders. Under the terms of the agreement, C4XD will receive an upfront payment of $10 million and could receive up to $284 million...